Natrise 15 mg (Tolvaptan)

Product Overview

Natrise 15 mg is a prescription tablet manufactured by Sun Pharmaceutical Industries Ltd. It is formulated for the management of the syndrome of inappropriate antidiuretic hormone secretion, commonly abbreviated as SIADH. The product is supplied in a strip containing four tablets, each delivering a dose of 15 mg of the active ingredient tolvaptan. Pack sizes are available in 28, 56, and 84 tablets, allowing patients and clinicians to select the most appropriate quantity for ongoing therapy. Natrise is classified under the hormonal disease category and is distributed with a standard packaging design that emphasizes safety and ease of use.

What is Natrise 15 mg (Tolvaptan)

Tolvaptan belongs to a class of medicines known as vasopressin V2 receptor antagonists. It functions by blocking the action of antidiuretic hormone at the V2 receptor in the collecting ducts of the kidney. This blockade prevents water reabsorption, leading to an increase in urine output and a consequent rise in serum sodium concentration. The drug is administered orally, and its pharmacological profile has been extensively studied in clinical trials that demonstrate its efficacy in correcting hyponatremia associated with SIADH.

Uses and Benefits

The primary therapeutic use of Natrise 15 mg is the correction of serum sodium levels in adult patients diagnosed with SIADH. By promoting water diuresis, the medication helps to alleviate the dilutional symptoms that can cause headache, nausea, confusion, and in severe cases, seizures. Early restoration of normal sodium balance can reduce hospital length of stay and lower the risk of neurological complications. In addition, Natrise has been investigated for off‑label applications in conditions such as polycystic kidney disease and certain forms of heart failure, although these uses remain investigational and should only be pursued under specialist supervision.

How It Works

Tolvaptan exerts its effect by selectively inhibiting the V2 subtype of the vasopressin receptor that regulates water permeability in the renal collecting ducts. When this receptor is blocked, the body excretes free water without accompanying solute loss, a process termed aquaresis. The resulting increase in free water clearance leads to a rise in serum sodium concentration, typically at a rate of 4–8 mmol/L per 24 hours when used according to recommended protocols. This mechanism distinguishes tolvaptan from other hyponatremia treatments that target sodium transport or osmotic stimuli.

Dosage Guidelines

Dosage of Natrise must be individualized based on the patient’s baseline sodium level, clinical response, and any underlying liver disease. The usual starting dose for adults is 15 mg taken once daily, which may be titrated upward in increments of 7.5 mg at intervals of at least 24 hours, aiming for a maximum daily dose of 60 mg. Serum sodium should be checked within 2 days of initiating therapy and thereafter at regular intervals to avoid overly rapid corrections, which can precipitate osmotic demyelination syndrome. Patients with moderate to severe hepatic impairment are advised to start at a lower dose of 7.5 mg daily, reflecting the drug’s metabolism through the liver. For detailed prescribing information, see the FDA label (FDA).

Side Effects

Like all prescription medicines, Natrise can be associated with adverse effects. The most frequently reported side effects include dry mouth, increased thirst, constipation, and mild hypotension. More serious reactions may involve liver enzyme elevations, hepatic failure, and hyponatremia that worsens despite therapy. Rarely, patients experience allergic skin reactions such as rash or urticaria. If any of these symptoms develop, especially signs of liver dysfunction such as jaundice or abdominal pain, medical attention should be sought promptly. For a comprehensive list of side effects, refer to reputable drug databases such as MedlinePlus (MedlinePlus).

Warnings and Precautions

Prior to prescribing Natrise, clinicians should assess hepatic function, volume status, and the presence of any contraindications such as anuria or severe hypovolemia. The medication is contraindicated in patients with liver cirrhosis who are not on dialysis, as well as in those with a known hypersensitivity to tolvaptan. Pregnant women should only use the drug if the potential benefit justifies the risk, and breastfeeding is not recommended while taking Natrise. Concomitant use with strong CYP3A4 inhibitors may increase tolvaptan exposure, necessitating dose adjustments. Additional cautions include monitoring for signs of osmotic demyelination during rapid sodium correction and ensuring adequate hydration status to prevent over‑diuresis. For detailed safety information, consult the FDA’s drug label (FDA).

Frequently Asked Questions

1. What is the recommended starting dose of Natrise 15 mg? The typical starting dose is 15 mg once daily, which may be adjusted based on serum sodium response.
2. Can Natrise be used in patients with liver disease? Patients with moderate to severe hepatic impairment should start at 7.5 mg daily and be monitored closely.
3. How quickly does serum sodium improve after taking Natrise? An increase of 4–8 mmol/L per 24 hours is expected when the drug is used as directed.
4. Are there any dietary restrictions while on Natrise? No specific dietary restrictions are required, but patients should maintain adequate fluid intake as advised by their clinician.
5. Is Natrise safe during pregnancy? Natrise should only be used during pregnancy if the expected benefit outweighs the potential risk, and a healthcare professional should be consulted.

Related Products

• Vortidif 20 Mg (Vortioxetine)
• Vortidif 5 Mg (Vortioxetine)
• Pramipex 0.25 mg (Pramipexole)
• Mirtaz 30 Mg (Mirtazapine)
• Lurasidone 40 mg (Generic)
• Ropinirole 1 mg (Generic)
• Adesam 200 mg (Ademetionine/S-Adenosyl Methionine)
• Suminat 25 mg (Sumatriptan)
• Syncapone 100 mg (Levodopa/Carbidopa/Entacapone)
• Cyclomune Eye Drop (Cyclosporin)
• Glypride 4 mg (Glimepiride)
• Tolvasca 15 mg (Tolvaptan)